Abingdon Health PLC (AIM:ABDX) CEO Dr Chris Hand talked with Proactive at the One2One Investor Forum about the company’s strong recent performance and expanding capabilities in the MedTech sector.
The discussion covered the company’s 45% revenue growth in the first half of the financial year, driven by multiple large contract wins and a broadened full-service offering following strategic acquisitions in 2024.
Dr Hand outlined how Abingdon Health, a specialist in lateral flow diagnostics, now delivers comprehensive services including contract development, regulatory strategy, and manufacturing. “We’ve extended the CDMO proposition to a full-service offering… and we’re finding an increasing number of larger full-service contract wins,”.
The company’s recent expansion into the US is already yielding results, with six active projects and a significant $2 million contract secured since launch. Dr. Hand noted that 40% of the global diagnostics market is in the US, highlighting the importance of a domestic presence.
Other key developments included the launch of eco-friendly lateral flow tests using red seaweed instead of plastic, the rollout of a smartphone reader app for semi-quantitative test interpretation, and contract wins in sectors ranging from malaria to sexually transmitted infections and avian flu.
#abingdonhealth #medtech #diagnostics #lateralflow #biotechnews #healthcareinnovation #usmarket #contractdevelopment #regulatoryservices #greentech #investing #proactiveinvestors
